Your cart is empty
Start Shopping$120.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
CAS Number | 910463-68-2 |
Molar Mass | 4,113.64 g/mol |
Amino Acid Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
PubChem CID | 56843331 |
Primary Research Area |
GLP-1 Receptor Agonist Type 2 Diabetes Mellitus (T2DM) Treatment Chronic Weight Management (Overweight/Obesity) Reduction of Major Adverse Cardiovascular Events Slow Gastric Emptying Increase Pancreatic β-cell Proliferation Reduce Glucagon Release Influence Hypothalamic Pathways (Appetite/Satiety) |
Purity | >99% |
Research Summary | Description |
---|---|
Once-weekly semaglutide in adults with overweight or obesity |
Summary: The STEP 1 trial showed a mean weight loss of 14.9% with once-weekly subcutaneous semaglutide 2.4 mg in individuals with overweight or obesity without type 2 diabetes. Citation: Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I.,... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. |
Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial |
Summary: The STEP 8 trial directly compared subcutaneous semaglutide (Wegovy®) to subcutaneous liraglutide for weight loss. Semaglutide proved superior, achieving a mean weight loss of -15.8% compared to -6.4% with liraglutide. Citation: Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rowe, E., Bartley, D.,... & STEP 8 Investigators. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. |
Oral Semaglutide and cardiovascular outcomes in high-risk |
Summary: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. Citation: Husain, M., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A.,... & PIONEER 6 Investigators. (2019). Oral Semaglutide and Cardiovascular Outcomes in High-Risk. New England Journal of Medicine, 381(9), 842-851. |
Semaglutide for the treatment of overweight and obesity: A review |
Summary: This review highlights that among patients who persisted with semaglutide for obesity, the average reduction in body weight was -12.9% at one year, compared to -5.9% with semaglutide for type 2 diabetes. Citation: Gasoyan, H., Kim, J., & Kim, Y. (2024). Semaglutide for the treatment of overweight and obesity: A review. Obesity Reviews, 25(10), e13788. |
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial |
Summary: In individuals with both overweight/obesity and type 2 diabetes, the STEP 2 trial reported a mean weight loss of -9.6% with semaglutide 2.4 mg and a mean HbA1c reduction of 1.6%. Citation: Davies, M., Færch, L., Jeppesen, O. K., Pakarinen, M., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. |
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes |
Summary: The SUSTAIN 6 trial investigated semaglutide's cardiovascular benefits in patients with T2DM. It demonstrated a reduction in a composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Citation: Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, J. A.,... & SUSTAIN 6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. |
Summary: The STEP 1 trial showed a mean weight loss of 14.9% with once-weekly subcutaneous semaglutide 2.4 mg in individuals with overweight or obesity without type 2 diabetes.
Citation: Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I.,... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
Summary: The STEP 8 trial directly compared subcutaneous semaglutide (Wegovy®) to subcutaneous liraglutide for weight loss. Semaglutide proved superior, achieving a mean weight loss of -15.8% compared to -6.4% with liraglutide.
Citation: Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rowe, E., Bartley, D.,... & STEP 8 Investigators. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150.
Summary: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events.
Citation: Husain, M., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A.,... & PIONEER 6 Investigators. (2019). Oral Semaglutide and Cardiovascular Outcomes in High-Risk. New England Journal of Medicine, 381(9), 842-851.
Summary: This review highlights that among patients who persisted with semaglutide for obesity, the average reduction in body weight was -12.9% at one year, compared to -5.9% with semaglutide for type 2 diabetes.
Citation: Gasoyan, H., Kim, J., & Kim, Y. (2024). Semaglutide for the treatment of overweight and obesity: A review. Obesity Reviews, 25(10), e13788.
Summary: In individuals with both overweight/obesity and type 2 diabetes, the STEP 2 trial reported a mean weight loss of -9.6% with semaglutide 2.4 mg and a mean HbA1c reduction of 1.6%.
Citation: Davies, M., Færch, L., Jeppesen, O. K., Pakarinen, M., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.
Summary: The SUSTAIN 6 trial investigated semaglutide's cardiovascular benefits in patients with T2DM. It demonstrated a reduction in a composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Citation: Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, J. A.,... & SUSTAIN 6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.
Your cart is empty
Start Shopping